Skip to main content

Partial sciatic nerve ligation leads to an upregulation of Ni-resistant T-type Ca currents in capsaicin-responsive nociceptive dorsal root ganglion neurons.

Journal of pain research

Authors: Monika Jeub, Omneya Taha, Thoralf Opitz, Ildiko Racz, Julika Pitsch, Albert Becker, Heinz Beck

BACKGROUND: Neuropathic pain resulting from peripheral nerve lesions is a common medical condition, but current analgesics are often insufficient. The identification of key molecules involved in pathological pain processing is a prerequisite for the development of new analgesic drugs. Hyperexcitability of nociceptive DRG-neurons due to regulation of voltage-gated ion-channels is generally assumed to contribute strongly to neuropathic pain. There is increasing evidence, that T-type Ca-currents and in particular the Ca3.2 T-type-channel isoform play an important role in neuropathic pain, but experimental results are contradicting.

PURPOSE: To clarify the role of T-type Ca-channels and in particular the Ca3.2 T-type-channel isoform in neuropathic pain.

METHODS: The effect of partial sciatic nerve ligation (PNL) on pain behavior and the properties of T-type-currents in nociceptive DRG-neurons was tested in wild-type and Ca3.2-deficient mice.

RESULTS: In wild-type mice, PNL of the sciatic nerve caused neuropathic pain and an increase of T-type Ca-currents in capsaicin-responsive neurons, while capsaicin-unresponsive neurons were unaffected. Pharmacological experiments revealed that this upregulation was due to an increase of a Ni-resistant Ca-current component, inconsistent with Ca3.2 up-regulation. Moreover, following PNL Ca3.2-deficient mice showed neuropathic pain behavior and an increase of T-Type Ca-currents indistinguishable to that of PNL treated wild-type mice.

CONCLUSION: These data suggest that PNL induces an upregulation of T-Type Ca-currents in capsaicin-responsive DRG-neurons mediated by an increase of a Ni-insensitive current component (possibly Ca3.1 or Ca3.3). These findings provide relevance for the development of target specific analgesic drugs.

PMID: 30804682

Participating cluster members